Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Epinastine and Pseudoephedrine Fixed Combination
NCT02182531Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 1999
- Primary completion
- Oct 1999
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of epinastine and pseudoephedrine in allergic rhinitis (AR) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the curve and Index of the absorption rate. Started Aug 1999; status: completed.
02
Drugs
epinastinepseudoephedrine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02182531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182531.